Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 13, 2026
- Accession no.
- 0001628280-26-017694
- Filed
- Mar 13, 2026
- Trade date
- Mar 11-12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 9 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Common Stock | MOption exerciseAcquired | +6,226 | $2.39 | +$14,880.14 | 112,047 | Direct | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −17,310 | $26.11F2 | −$451,964.1 | 94,737 | Direct | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −1,357 | $26.11F2 | −$35,431.27 | 51,566 | Indirect | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −1,160 | $26.11F2 | −$30,287.6 | 43,826 | Indirect | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −282 | $26.11F2 | −$7,363.02 | 3,336 | Indirect | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −279 | $26.11F2 | −$7,284.69 | 3,336 | Indirect | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −279 | $26.11F2 | −$7,284.69 | 3,336 | Indirect | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −279 | $26.11F2 | −$7,284.69 | 3,336 | Indirect | |
| Mar 12, 2026 | Common Stock | SSaleDisposed | −23,179 | $25.28F9 | −$585,965.12 | 71,558 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Common Stock | MOption exerciseDisposed | −6,226 | $0.00 | $0 | 14,282 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $24.900 to $25.705, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.